anticancer agent 3

Anticancer agent 3 (Compound 4) is an anticancer agent.

Anticancer Agent 110 exhibits potent in vitro anti-leukemia activity, demonstrating high cytotoxicity against K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. It induces DNA damage and subsequently triggers apoptosis [1].

(S)-5-chloro-N-(1-((4-chlorophenyl)amino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide has antifungal and tuberculostatic activities.

Anticancer agent 174 (BA-3) functions as a potent inhibitor of cancer cell proliferation and induces apoptosis via the mitochondrial pathway in melanoma mouse xenograft models [1].

Anticancer Agent 153 (Compound 3) promotes apoptosis through the generation of Reactive Oxygen Species (ROS) and elevates the loss of Mitochondrial Membrane Potential (MMP), effectively inhibiting cancer cell proliferation [1].

Anticancer agent 40 (compound 3e) is a potent anticancer agent with effects on SKBR-3 cells (IC50: 0.94 nM), SKOV-3 cells (IC50: 0.98 nM), PC-3 cells (IC50: 0.96 nM), U-87 cells (IC50: 0.95 nM), and HDF cells (IC50: 2.13 nM).

Anticancer agent 30 (compound 6f-Z) is a potent 3-arylidene-2-oxindole derivative that acts as a selective CDK2 inhibitor, showing significant anticancer activity and potential as a cancer treatment [1].

Anticancer agent 137 (8q), a potent PI3k inhibitor, exhibits broad-spectrum anticancer activity by inducing G2/M cell cycle arrest and apoptosis. It increases levels of cleaved PARP, and caspases 3 and 7, making it useful in cancer research [1].

Anticancer agent 33 (compound 3), derived from Squamocin and Bullatacin, exhibits potent inhibitory activity against the 4T1 breast cancer cell line (A549, HeLa, HepG2, and MCF-7 cells) with IC50 values ranging from 1.9 to 5.4 µM [1].

Anticancer Agent 149 (compound 3), isolated from the rhizome of Dioscorea dioscorea (DM), demonstrates selective cytotoxicity against MCF-7 cells with an IC50 of 31.41 μM [1].

Compound 5cb, known as Anti-melanoma agent 3, is a derivative of 2-aryl-4-benzoyl-imidazole (ABI) that acts as an inhibitor of melanoma xenogeneic tumors. It exhibits anticancer effects by targeting the colchicine binding site, thereby preventing tubulin polymerization [1].

Compound 6j (Anticancer agent 147), a sophoridine derivative and ferroptosis inducer, promotes intracellular accumulation of Fe2+, reactive oxygen species (ROS), and malondialdehyde (MDA), enhances endoplasmic reticulum (ER) stress, and upregulates activating transcription factor 3 (ATF3) expression, demonstrating potent anti-liver cancer effects both in vitro and in vivo [1].

Anticancer agent 56 (compound 4d) is a powerful anti-cancer compound with favorable drug-like properties, showing significant anticancer activity against multiple cancer cell lines with an IC50 value of less than 3 μM. It exerts its effects by causing cell cycle arrest at the G2 M phase and activating the mitochondrial apoptosis pathway, inducing the accumulation of reactive oxygen species (ROS), upregulating BAX, downregulating Bcl-2, and triggering the activation of caspases 3, 7, and 9 [1].

Anticancer agent 63 (compound 3h) exhibits significant cytotoxic activity against multiple cancer cell lines, including SW480, HeLa, A549, and MCF-7, with IC50 values of 4.9, 11.5, 9.4, and 3.4 μM, respectively, after 24 hours of treatment. It induces apoptosis in MCF-7 cells by down-regulating Bcl-2 expression and up-regulating IL-2 and Caspase-3 expression, and also demonstrates antioxidative properties [1].

Anticancer agent 58 exhibits inhibitory activity against various cancer cell lines, particularly A549 and T24, with IC50 values of 0.6 μM and 0.7 μM, respectively. It promotes apoptosis through the activation of caspase 3/8/9, and elevates levels of Ca2+ and ROS within cancer cells. Additionally, it significantly reduces mitochondrial membrane potential and suppresses tumor growth in the T24 mouse xenograft model.

Anticancer agent 76 (Compound CT2-3) significantly inhibits proliferation, induces cell cycle arrest, ROS production, and apoptosis in human NSCLC cells.

Anticancer agent 111 (compound 11), exhibiting anticancer activity, serves as a potent inhibitor of cytochrome P450, particularly targeting CYP3A4 with an inhibitory concentration (IC50) of 3 μM. It is useful in cancer research [1].

Anticancer agent 43 is a potent anticancer agent that induces apoptosis through caspase 3, PARP1, and Bax protein-dependent pathways.Anticancer agent 43 induces DNA damage and can be used in the study of glioblastoma in rats.

Anticancer agent 64 (compound 5m) exhibits potent cytotoxicity against CCRF-CEM cells with an IC50 value of 2.4 μM, induces apoptosis by activating caspase 3 and 7 and causing PARP cleavage, and significantly disrupts mitochondrial membrane potential, thereby contributing to its anticancer efficacy [1].

Anticancer agent 129 (Compound 3a) is a quinoline derivative predicted to have anti-cancer activity [1].

Anticancer agent 136 (compound 22), a C17-triazole analogue of Geldanamycin (GDM), exhibits an IC50 value of 3.38 μM against human dermal fibroblasts (HDF) and binds to Heat shock protein 90 (Hsp90) with a dissociation constant (Kd) of 3.86 μM, demonstrating its apoptosis-inducing capabilities [1].

Anticancer Agent 108 (Compound 3.10) serves as a potent P-gp inhibitor exhibiting considerable antitumor properties while maintaining reduced toxicity to both normal and pseudonormal cells; it also demonstrated no acute toxic effects on C57BL/6 mice [1].

Anticancer Agent 146 (Compound 1.19) acts as a necroptosis inducer and demonstrates anti-tumor efficacy in the MDA-MB-231 mouse xenograft model [1].

Compound 103 (Compound 2k) serves as a potent anticancer agent [1].

Anticancer agent 112[1], serves as a potent agent for cancer research.

Anticancer agent 32 (compound 2g) is an anticancer compound that affects the cell cycle and induces apoptosis, making it valuable for cancer research.

Anticancer agent 74 exhibits moderate anticancer activity with lower selectivity and cytotoxicity compared to doxorubicin towards normal cells [1].

Anticancer agent 49 (compound 69) is a broad-spectrum anticancer agent with anti-proliferative activity. Anticancer agent 48 inhibits microtubule protein aggregation and has in vivo antitumour activity, with potential for studies on solid tumours and haematological tumours.

Anticancer agent 66, a ciprofloxacin analog, functions as an anti-cancer agent by inducing apoptosis and elevating the sub-G1 cell population in MCF-7 cells.

Anticancer agent 59, an inhibitor active against various cancer cell lines, particularly demonstrates efficacy in A549 cells with an IC 50 value of 0.2 μM. It prompts apoptosis, elevates Ca2+ and ROS levels within cancer cells, and markedly reduces mitochondrial membrane potential. Additionally, it effectively curtails tumor growth in the A549 mouse xenograft model.

Anticancer agent 70 (Compound 21) is a potent anticancer compound that demonstrates remarkable cytotoxicity against multiple human cancer cell lines. It induces G0/G1-cell cycle arrest and concurrently elevates the levels of p53 and p21 proteins. Furthermore, Anticancer agent 70 induces ATP depletion and disruption of the mitochondrial membrane potential [1].

Anticancer Agent 102, a tetracaine derivative, exhibits anti-cancer activity by inducing apoptosis [1].

Anticancer agent 81 (Compound 37b3) induces tumor cell cycle arrest and apoptosis, and serves as a payload for conjugation with Trastuzumab, forming the antibody-drug conjugate (ADC) T-PBA, which retains Trastuzumab's targeting and internalization properties [1].

Antiproliferative agent-3 (comp 4) exhibits potent growth inhibitory effects against MCF-7 cells with an IC50 of 0.19 nM [1].

Anticancer agent 29 (Compd E Z-6f) exhibits potent anticancer activity with IC50 values of 0.054 μM, 0.127 μM, 0.129 μM, and 0.396 μM for CDK2, CDK1, CDK4, and CDK6, respectively [1].

Anticancer agent 38 (compound 19) is an aryl-urea compound, and is a potent anticancer agent. Anticancer agent 38 inhibits A431 cell growth with an IC 50 of 5.2 μg/mL [1].

Anticancer agent 54 is an effective anticancer agent whose anticancer activity depends on DNA embedding and ROS generation. Anticancer agent 54 has an anti-proliferative effect by blocking the cell cycle in G0/G1 phase and inducing apoptosis.

Anticancer agent 57 (compound 14) demonstrates potent inhibition of MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC50 values ranging from 6.43 to 8.00 μM. Additionally, this agent induces cell cycle arrest and promotes apoptosis. In vivo studies using nude mice xenografted with MADMB-231 cells have shown that Anticancer agent 57 effectively inhibits tumor growth. Consequently, Anticancer agent 57 can serve as a valuable tool for researching triple negative breast cancer (TNBC) [1].

Anti-MRSA agent 3 inhibits methicillin-resistant Staphylococcus aureus (MRSA) activity significantly (MIC: 0.098 μg/ml) with low toxicity to normal cells. anti-MRSA agent 3 has a high binding affinity for bacterial genomic DNA and a strong ability to disrupt bacterial cell walls and membranes.

Anticancer agent 34 (compound 9) is a sulfonylurea derivative and a potent anti-microbial and anti-cancer agent. anticancer agent 34 showed inhibition of microbial growth of Mycobacterium, Escherichia coli and Candida albicans (MIC: 0.039-0.156 mg/ml). Anticancer agent 34 inhibited the growth of A549 cells (IC50: 8.4 μg/ml), PC3 cells (IC50: 7.8 μg/ml).

Anticancer agent 79 (compound 3d) is an anticancer compound with good anti-breast cancer activity, exhibiting cytotoxic activity in T47-D cells (IC50= 13.64 ± 0.26 μM).

Compound 3a, an anticancer agent and ketone derivative, exhibits potent activity against the A549 cancer cell line, demonstrating an inhibitory concentration (IC50) of 6.62 μM [1].

Compound 166, also referred to as compound 3, exhibits potent anticancer properties, demonstrating significant inhibitory activity against Caco-2 cells with an IC50 value of 9.6 nM [1].

Anticancer agent 160 (Compound 6), a natural product extracted from Parthenium hysterophorus, exhibits cytotoxicity against HCT-116 cells with an IC50 of 5.0 μM [1].

Compound 6i, an anticancer agent, exhibits promising activity against breast adenocarcinoma [1].

Antioxidant anticancer agent 1 (compound 5) is a Schiff base derivative of pyrimidine and pyrimidine hydroxy-1-naphthaldehyde, exhibiting antibacterial, antioxidant, antifungal, and anticancer properties [1].

Anticancer agent 109 (compound 6-15) acts as an inhibitor targeting the Gas6-Axl axis, demonstrating significant anti-cancer properties. This compound suppresses the expression of Gas6, Axl, p-PI3K, and p-AKT in cancer cells, thereby inducing G1 phase arrest and promoting apoptosis of cancer cells. Additionally, Anticancer agent 109 effectively inhibits tumor growth in nude mouse tumor-bearing models [1].

Anticancer agent 120 (compound 21), an N-acylated derivative of ciprofloxacin, exhibits antibacterial activity and promotes cancer cell apoptosis by inducing ROS [1].